CTRI/2015/05/005811已完成3 期
A phase 3, randomized, double-blind study of PF-05280586 versus Rituximab for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma - REFLECTIONS B328-06
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Confirmed diagnosis of low tumor burden, CD20-positive follicular lymphoma (containing no elements of diffuse large B-cell lymphoma)
- •Ann Arbor Stage II, III, or IV
- •Eastern Cooperative Oncology Group (ECOG) status of 0 to 1
- •At least 1 measureable disease lesion of at least 1.5 cm in longest diameter
排除标准
- •Not a candidate for treatment with rituximab as a single-agent
- •Evidence of transformation to a high grade or diffuse large B-cell lymphoma
- •Central nervous system or meningeal involvement or cord compression by the lymphoma.
- •T-cell lymphoma.
- •Any prior treatment for lymphoma
- •Any prior treatment with rituximab
- •Active, uncontrolled infection
研究者
相似试验
进行中（未招募）
3 期
A Study of PF-05280014 [Trastuzumab-Pfizer] or Herceptin® [Trastuzumab-EU] Plus Paclitaxel in HER2 Positive First Line Metastatic Breast Cancer TreatmentCTRI/2014/07/004786Pfizer Limited
进行中（未招募）
1 期
A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting.low tumor burden follicular lymphomaMedDRA version: 17.1 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-000132-41-HRPfizer Inc., 235 East 42nd Street, New York, NY 10017394
进行中（未招募）
1 期
A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting.low tumor burden follicular lymphomaMedDRA version: 17.1 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-000132-41-GBPfizer Inc., 235 East 42nd Street, New York, NY 10017394
进行中（未招募）
1 期
A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting.low tumor burden follicular lymphomaMedDRA version: 20.0 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-000132-41-PTPfizer Inc., 235 East 42nd Street, New York, NY 10017394
进行中（未招募）
1 期
A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting.EUCTR2014-000132-41-ESPfizer Inc., 235 East 42nd Street, New York, NY 10017394